Treatment of systemic lupus erythematosus: A 2012 update

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 3, 2012, Pages 172-176

  Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ESTROGEN; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; VITAMIN D;

AMENORRHEA; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLIC DISORDER; OSTEOPOROSIS; PLASMAPHERESIS; POSTMENOPAUSE OSTEOPOROSIS; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STEM CELL TRANSPLANTATION; STEROIDS; TREATMENT OUTCOME;

EID: 84869447491     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bertsias G, Ioannidis JP, Boletis J, et al. Eular Recommendations for the Management of SLE. Ann Rheum Dis. 2008 Feb;67(2):195-205.
2. Petri M. Treatment of Systemic Lupus Erythematosus: An Update. Am Fam Physician. 1998 Jun;57(11):2753-60.
3. Gordon C. Long Term Complications of Systemic Lupus Erythematosus. Rheumatology (Oxford). 2002 Oct;41(10):1095-100.
4. Gladman DD, Hussain F, Ibañez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus. 2002;11(4):234-9.
5. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin PharmacolTher. 1989 Aug; 46(2):149-54.
6. Yamamoto K, Okada Y, Nakamura K, et al. Inosine triphosphate pyrophosphatase 94C> A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin Drug Saf. 2010 May;9(3):447-57.
7. Kamar N, Faure P, Dupuis E, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int. 2004 Sep;17(8):463-7.
8. Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant. 2010 May;29(5):509-16.
9. Cutolo M, Sulli A, Pizzorni C, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum Dis. 2001 Aug;60(8):729-35.
10. Wiela-Hojenska A, Orzechowska-Juzwenko K, Swierkot J, et al. Monitoring methotrexate therapy in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004 Aug;42(8):434-41.
11. Zhang FS, Nie YK, Jin XM, et al. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int. 2009 Sep;29(11):1331-5.
12. Houssiau F, Dooley MA, Aranow C, D'Cruz D, Askanase A, Roth DA, Cooper S, Zhong ZJ, Freimuth W, Ginzler EM, and BLISS-52/-76 Study Groups. Post hoc analysis to assess effect of belimumab in patients on mycophenolate mofetil with renal manifestations at baseline. EULAR 2011 [SAT0192].
13. van Vollenhoven R, Schneider M, Wallace D, et al. Efficacy of belimumab in patinets with SLE: Focus on patients with low complement and positive anti-dsDNA-Results from BLISS 53/BLISS 76 EULAR 2011 [OP0167].
14. Schneider M, Buyon J, Dooley MA, et al. Impact of mycophenolate mofetil and/or corticosteroid treatment on outcomes of belimumab treatment in SLE. EULAR 2012 [SAT0195]
15. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jun 5. doi: 10.1002/art.34564. [Epub ahead of print].
16. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken).2012 Jun;64(6):797-808.
17. Liu LL, Jiang Y, Wang LN, et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012 Jul 30;72(11):1521-33.
18. Kamijo Y, Hashimoto K, Takahashi K, et al. Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis. Clin Nephrol. 2011 Aug;76(2):136-43.
19. Yap D, YU Y, Chen X, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012 May;17(4):352-7.
20. Lenz O, Waheed AA, Baig A, et al. Lupus Nephritis: Maintenance Therapy for Lupus Nephritis--Do We Now Have a Plan? Clin J Am Soc Nephrol. 2012 Aug 23. [Epub ahead of print].
21. Mascarenhas S, Avalos B, Ardoin SP. An Update on Stem Cell Transplantation in Autoimmune Rheumatologic Disorders. Curr Allergy Asthma Rep. 2012 Sep 6. [Epub ahead of print].
22. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.
23. Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2012 Sep 3. [Epub ahead of print].